Bellevue Group AG lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 18.2% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 46,027 shares of the biopharmaceutical company's stock after purchasing an additional 7,093 shares during the quarter. Bellevue Group AG's holdings in Gilead Sciences were worth $3,859,000 as of its most recent filing with the SEC.
Several other large investors also recently made changes to their positions in GILD. Manning & Napier Advisors LLC purchased a new position in Gilead Sciences in the 2nd quarter worth approximately $25,328,000. Legal & General Group Plc lifted its holdings in Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock worth $851,743,000 after buying an additional 93,068 shares in the last quarter. IRON Financial LLC acquired a new position in Gilead Sciences in the 3rd quarter worth $830,000. Wealth Enhancement Advisory Services LLC boosted its position in Gilead Sciences by 13.1% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company's stock valued at $19,630,000 after buying an additional 33,162 shares during the last quarter. Finally, Cetera Investment Advisers increased its position in shares of Gilead Sciences by 127.6% during the first quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company's stock worth $15,668,000 after acquiring an additional 119,909 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts recently commented on GILD shares. Oppenheimer increased their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an "outperform" rating in a report on Thursday, November 7th. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. UBS Group lifted their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a research note on Thursday, November 21st. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Finally, The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $74.00 to $84.00 and gave the stock a "neutral" rating in a research report on Thursday, November 7th. Twelve investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $95.41.
Read Our Latest Analysis on GILD
Insider Activity at Gilead Sciences
In related news, insider Merdad Parsey sold 2,000 shares of the firm's stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total transaction of $167,660.00. Following the transaction, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. This trade represents a 1.96 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the company's stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company's stock, valued at $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 227,946 shares of company stock worth $20,683,305 over the last ninety days. 0.16% of the stock is currently owned by corporate insiders.
Gilead Sciences Stock Performance
Shares of GILD stock traded up $0.17 during trading hours on Friday, reaching $92.58. The stock had a trading volume of 3,850,965 shares, compared to its average volume of 7,286,159. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The firm has a 50-day simple moving average of $88.26 and a 200-day simple moving average of $77.76. The firm has a market capitalization of $115.38 billion, a PE ratio of 1,028.67, a price-to-earnings-growth ratio of 2.87 and a beta of 0.17. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the previous year, the firm posted $2.29 earnings per share. The business's revenue was up 7.0% on a year-over-year basis. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 4.37 earnings per share for the current year.
Gilead Sciences Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.33%. The ex-dividend date is Friday, December 13th. Gilead Sciences's dividend payout ratio (DPR) is 3,422.22%.
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Featured Articles
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
